Presentation is loading. Please wait.

Presentation is loading. Please wait.

Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A)

Published byÉΘεοκλής Αλεξάκης Modified over 5 years ago

Similar presentations

Presentation on theme: "Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A)"— Presentation transcript:

1 Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. HRs are adjusted for prior CVD, education, sex, hypertension, waist and hip circumference, smoking, HDL cholesterol, triglycerides, and total cholesterol. Dianna J. Magliano et al. Dia Care 2010;33: ©2010 by American Diabetes Association

Download ppt "Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A)"

Similar presentations

1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.

1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.
RESULTS OF THE RIMONABANT IN OBESITY (RIO) PROGRAM AT 1 YEAR

RESULTS OF THE RIMONABANT IN OBESITY (RIO) PROGRAM AT 1 YEAR
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
End point Rimonabant 20 mg (n=339) Placebo (n=348) p Weight (kg) -5.3

End point Rimonabant 20 mg (n=339) Placebo (n=348) p Weight (kg) -5.3
Prehypertension, Diabetes, and Cardiovascular Disease Risk in a Population-Based Sample by Ying Zhang, Elisa T. Lee, Richard B. Devereux, Jeunliang Yeh,

Prehypertension, Diabetes, and Cardiovascular Disease Risk in a Population-Based Sample by Ying Zhang, Elisa T. Lee, Richard B. Devereux, Jeunliang Yeh,
Prospective associations of plasma phospholipid trans/trans-18:2 with total mortality, CVD and CHD before and after mutual adjustment without correction.

Prospective associations of plasma phospholipid trans/trans-18:2 with total mortality, CVD and CHD before and after mutual adjustment without correction.
Change (with 95% CI) in outcomes by duration of type 2 diabetes

Change (with 95% CI) in outcomes by duration of type 2 diabetes
WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,
Prevalence of statin and beta-blocker use by clinical presentation

Prevalence of statin and beta-blocker use by clinical presentation
Association between highest tertile for homocysteine and mortality

Association between highest tertile for homocysteine and mortality
Joshua A. Bell et al. JACC 2018;72:

Joshua A. Bell et al. JACC 2018;72:
Incidence of all renal events according to achieved BP levels, adjusted for age, gender, duration of diabetes, glycosylated hemoglobin, currently treated.

Incidence of all renal events according to achieved BP levels, adjusted for age, gender, duration of diabetes, glycosylated hemoglobin, currently treated.
NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:1212-8.

NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:
Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.

Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.
Baseline Characteristics According to Sex

Baseline Characteristics According to Sex
Comparison of clinical and functional parameters between the CMV+ and CMV− participants in the healthy elderly and elderly patients with T2DM. Comparison.

Comparison of clinical and functional parameters between the CMV+ and CMV− participants in the healthy elderly and elderly patients with T2DM. Comparison.
(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.
Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.
Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.
Relative risk of a major coronary heart disease event (myocardial infarction incidence, fatal coronary heart disease, or coronary revascularization) for.

Relative risk of a major coronary heart disease event (myocardial infarction incidence, fatal coronary heart disease, or coronary revascularization) for.

Similar presentations

Ads by Google